跳至主要内容
临床试验/NCT03333655
NCT03333655已完成4 期

A Multicenter Study to Explore the Mechanism of Acquired Immune Escape In Patients With Metastatic Cancer Progressing on Checkpoint Inhibitor Therapy

Hoffmann-La Roche21 个研究点 分布在 5 个国家目标入组 15 人开始时间: 2018年2月16日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
15
试验地点
21
主要终点
Number of Gene Alterations in at-Progression Biopsy of Patricipants with Acquired Immune Escape

研究概览

简要总结

The purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from CPI treatment of metastatic cancer or hematologic malignancies.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Response assessment of complete response (CR), partial response (PR), or long-term stable disease (SD) for >6 months with a cancer immunotherapy treatment for metastatic cancer or hematologic malignancies either through a marketed CPI or through participation in a Roche/Genentech CPI clinical trial.
  • Availability of tissue sample.

排除标准

  • Pregnant, lactating, or intending to become pregnant during the study.
  • Participants receiving CPI treatment as part of a non-Roche/Genentech clinical trial.

结局指标

主要结局

Number of Gene Alterations in at-Progression Biopsy of Patricipants with Acquired Immune Escape

时间窗: Day 1

Number of Gene Alterations Will Be Evaluated Using NGS Approaches by Comparing At-Progression Biopsy with Pre-Treatment Biopsy

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (21)

Loading locations...

相似试验